ExpreS2ion’s CEO in interview on 2019 and the company’s new way forward with a stronger pipeline focus
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) publishes an interview with newly appointed CEO Bent Frandsen upon shareholder request. The company’s new way forward with Bent at the helm will include a much stronger focus on building a pipeline portfolio with assets developed in the ExpreS2 platform.
The CEO interview is available via this link: https://mailchi.mp/expres2ionbio.com/january2020
This interview is a part of ExpreS2ion’s efforts to improve its communication with shareholders and others interested in the company in 2020 and thereafter.
For additional information, please contact
ExpreS2ion Biotech Holding AB
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telephone: +46 70 755 95 51
E-mail: ca@skmg.se
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatory validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.
